Vmbook Online ordering

Vanda Pharmaceuticals Inc

Versartis, Inc. (VSAR) is a biopharmaceutical company based in the United States, that is focused on the discovery and development of complex molecules for the treatment of various diseases and conditions. The company's stock is listed on the NASDAQ stock exchange under the ticker symbol "VSAR".

In terms of financials, Versartis reported a net loss of $53.5 million for the full year 2020, compared to a net loss of $72.5 million for the full year 2019. As of December 31, 2020, the company had cash, cash equivalents and investments of $112.6 million.

The company's main product is Somavaratan, a long-acting recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD) in children and adults. However, in 2020, the company announced it will discontinue the development of Somavaratan after the phase 3 trial did not meet its primary endpoint.

The company is currently working on other pipelines, but there are no approved products and revenues.

It is important to note that biotech companies, especially those in clinical stages, are subject to a high degree of risk and uncertainty, and their financial performance can be highly variable due to the nature of their business and the regulatory environment. Therefore, it's important to conduct further research and consult with a financial advisor before making any investment decisions.